

s22(1)

RECEIVED

- 9 NOV 2015

Medicines Reg

Division: *Medicines Reg*

Minister: *Nash*

Milestone: 10 15 20

INFO

VI:

PM

Minister for Rural Health

09 NOV 2015

Reply by

Minister

Chief of Staff

Adviser

Action

Response

Phone Call

Information

Department

Urgent by

Other

Campaign

Constituent

Background Information

Required

Refer to

Comments:

s22(1)

To
 The Commonwealth Attorney-General
 Senator the Hon. George Brandis QC

PO Box 6100
 Senate
 Parliament House
 CANBERRA ACT 2600

Dear Sir,

Pfizer's CHAMPIX – CHANTIX
Varenicline

s22(1)

[Redacted]

they should black label their product Champix

[Redacted]

TESTING

The FDA (USA) have advised Pfizer that the clinical testing provided was not detailed enough and too small. We were told that Pfizer are conducting new clinical test for Pfizer by Pfizer & would be finished by December 2017. Now it will released December 2015. **WHY WAIT, we have had 9 years of real life human testing happening around the Globe. RESULT, 100's dead, 1,000's have had adverse effects. ANSWER: Pfizer stuffed up and the product should be removed from the market (s)** s22(1)

CHAMPIX APPROVAL by the TGA

Something is **VERY WRONG HERE** with the TGA approval of Pfizer's Champix for sale & inclusion in the PBS.

FDA (USA), HEALTH CANADA (Marketed Health Products Directorate), MINISTER for HEALTH, (U.K.), MINISTER for HEALTH (France), have all insisted on a "Black Box warning" label be placed on Pfiser's CHANTIX – CHAMPIX PACKAGING.

The FDA has rejected Pfizer's request to remove the Warning Label due to inadequate clinical testing. The FDA are awaiting the results due in December 2015, originally due in 2017.

Australia's TGA's ASCOM 15 (Part time) committee members, who approve drugs for sale & recommend to be listed on the PBS Have ignored other countries WARNINGS & Adverse reaction data, & HAVE APPROVED CHAMPIX for sale & listed on the PBS WITHOUT WARNINGS.

WHY?

This committee made up of 8 Professors, 6 Doctors & a member of the National Immunisation Committee meet six times per annum to decide on a drugs suitability for Australians & that all stringent Rules, regulations & testing have been carried out.

what is the common denominator here.

1. All members of the Committee are employed by
 1. Hospitals
 2. Universities
 3. Research Institutions
2. All rely on donations or (GRANTS) to survive & continue in their professions chosen.
3. Pfizer & other drug manufacturers give out "GRANTS".

I believe this is a "CONFLICT of INTEREST"

I also believe that these members have broken their OATH by allowing Champix to be approved.

Yours Sincerely

s22(1)



Pages 4-5 inclusive exempt in full under section 22(1) of the FOI Act (irrelevant information)

MPEG

From: MPEG
Sent: Monday, 9 November 2015 10:34
To: 'Ministerial Correspondence Unit'
Subject: RE: Referral from AGD MC15-008315 - HAMBLIN V's Pfizer (CHAMPIX)
[SEC=UNCLASSIFIED]

Hi s22(1)

The Department of Health accepts this referral.

Thanks

[REDACTED]
[REDACTED]
Allocations Team
Ministerial, Parliamentary, Executive Support and Governance Branch
Department of Health
[REDACTED]

From: Ministerial Correspondence Unit s22(1)
Sent: Monday, 9 November 2015 9:00 AM
To: Referrals
Subject: Referral from AGD MC15-008315 - s22(1) V's Pfizer (CHAMPIX) [SEC=UNCLASSIFIED]

UNCLASSIFIED

Good morning,

The Attorney-General has received the attached correspondence.

It is considered that the matter raised may more appropriately fall within the portfolio responsibilities of your Minister/Department.

The correspondence has been referred for the attention of your Minister/Department and direct reply if necessary. An acknowledgement letter has not been sent.

Please note the Attorney-General's Department now uses an electronic process, therefore no hard copies will be sent.


If a response has not been received within five business days, we will consider it as being accepted by your department.

Kind regards,

s22(1)

Ministerial and Executive Support Section (MES)

s22(1)



s22(1)



Pages 8 exempt in full under section 22(1) of the FOI Act (irrelevant information)